Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a weight loss drug. The data readouts from that program alone were enough to convince quite a few investors to buy the stock.

And now there's a brand-new reason to invest -- perhaps an even better one than before. Let's investigate what's new and why it matters.

For the uninitiated, Viking's program -- called VK2735 -- is a highly promising therapy for obesity. It's being evaluated in two formulations in clinical trials, one that is injected on a weekly basis and the other being a once-daily pill.

Continue reading

Source Fool.com